What effect does Wegovy actually have — and how soon does it show?

The biggest myth: 'I should feel a strong effect from week one'

Most people starting Wegovy expect a noticeable appetite shift from the very first injection. That expectation is understandable, but it misreads how the medicine works. Wegovy's titration schedule starts at 0.25mg, a dose selected primarily to let your body adjust rather than to produce significant appetite suppression. The real therapeutic effect accumulates as the dose climbs (through 0.5mg, 1.0mg, 1.7mg) and only reaches its full potential at the 2.4mg maintenance level, which most patients arrive at after roughly four months of gradual increases.

This phased approach is not a weakness in the medicine. It exists because moving too quickly to higher doses produces far more nausea, vomiting and stomach discomfort than most people would accept. The early weeks are calibration. Expecting dramatic weight loss before reaching maintenance is a bit like expecting full heating from a radiator that's only just warming up.

A question our prescribers hear most weeks is some version of: 'I've been on it three weeks and nothing's changed, is it working?' The answer, almost always, is that it is working exactly as intended. Patience with the titration period is one of the most important things to carry into treatment. If you are genuinely seeing no appetite change at any point during the build-up, that is worth flagging to your prescriber, you can read more about when Wegovy seems to have no effect and what might be behind it.

What the Wegovy effect actually feels like in practice

Once established at a therapeutic dose, the effect of semaglutide is not dramatic in the way people sometimes imagine. It is quieter than that. Hunger signals arrive less urgently. Portions that previously felt modest now feel adequate. The mental pull toward food between meals (what researchers call 'food noise') reduces for many people. Cravings do not disappear entirely, but they become easier to step back from.

The semaglutide overview on this site covers the mechanism in more detail, but in everyday terms the effect is less about willpower feeling easier and more about appetite biology genuinely shifting. GLP-1 receptors are present in both the gut and the brain, and semaglutide acts on both. Gastric emptying slows, so food stays with you longer. Satiety signals arrive sooner after eating. Some people also notice a modest improvement in energy, though that tends to be a secondary effect of losing weight rather than a direct drug effect.

The full range of effects associated with Wegovy (including cardiovascular and liver-related indications that have received UK regulatory approval since 2023) goes beyond weight loss alone, though weight management remains the primary reason most patients use it.

Timeline: when does the weight-loss effect become measurable?

Clinical trial data from the STEP 1 study, published in the New England Journal of Medicine, showed an average weight reduction of around 15% over 68 weeks at 2.4mg. That figure is an average across the whole trial period; in practice, the steepest rate of loss tends to occur once someone has reached or is approaching maintenance dose, with loss continuing (though often slowing) as treatment progresses.

For most people, a noticeable effect on the scales tends to emerge around weeks 8 to 12, assuming regular injections and no major dietary changes working against the medicine. Weight loss before that point is possible but variable. If you want a clearer picture of the progression, the page on how long Wegovy takes to work goes through the timeline in more detail, including what to expect at each dose step.

The MHRA's approval of a 7.2mg maintenance dose in April 2026 opens a new chapter for people who reach a plateau at 2.4mg. Trials reported around 20.7% average weight loss over 72 weeks at the higher dose, approaching the results seen with tirzepatide. Whether that dose is appropriate for a given patient is a clinical decision. You can find more on how effective Wegovy is compared with other options currently available in the UK.

Side effects and what they mean for the treatment effect

The most common effects of Wegovy are gastrointestinal: nausea, constipation, diarrhoea, reflux and, for some people, tiredness or mild headaches, particularly in the first days after an injection or after a dose increase. These are reviewed thoroughly on the Wegovy treatment page. In the majority of cases they are temporary, easing within a week or two as the body adapts. They are also, to some extent, a sign the medicine is doing its job, slowing gastric emptying produces fullness but can also produce nausea.

Worth noting from the NHS guidance on semaglutide: severe, persistent stomach pain that spreads to your back, with or without vomiting, should be assessed urgently, this is a symptom pattern associated with pancreatitis, a rare but serious condition. The MHRA flagged acute pancreatitis as a known risk for GLP-1 medicines in a January 2026 safety update. For anyone managing ongoing side effects or wondering whether what they are experiencing is within normal range, our support team is available seven days a week.

If you are weighing up whether Wegovy is the right route given cost, the Wegovy price comparison page gives honest context on what private treatment typically costs in the UK and what to look for in a provider. For those ready to talk to a clinician, speaking to our prescribers is the straightforward next step.